sellWeak cluster of 210b5-1 plan
Richard Scott Struthers sold $180k of CRNX
President & CEO at Crinetics Pharmaceuticals, Inc.. 4,000 shares at an average of $45.00, traded Sep 26, 2025, filed Sep 30, 2025.
Warning score
25Value
$180k
4,000 shares
Holdings after
106,000
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +12Trade size$180k at market
- 0Share of holdings soldSold 3.6% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001658247-25-000011, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 26, 2025 | SOpen-market sale Common Stockindirect: By Family Trust 210b5-1 | -4,000 | $45.00 | $180k | 106,000 | Sep 30, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | $716k 16,000 shares | -41% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $161k 5,000 shares | -5% | |
| 14Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $913k 30,000 shares | -31% | |
| 7Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $189k 6,492 shares | -9% | |
| 15Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $3.1M 97,483 shares | -49% | |
| 22Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $197k 5,770 shares | -5% | |
| 39Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $593k 17,338 shares | -5% | |
| 28Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $245k 7,162 shares | -8% | |
| 19Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $86k 2,515 shares | -3% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $195k 5,000 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.